Alberta Investment Management Corp Sells 28,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Alberta Investment Management Corp lessened its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 23.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 91,100 shares of the company’s stock after selling 28,000 shares during the period. Alberta Investment Management Corp’s holdings in Teva Pharmaceutical Industries were worth $1,527,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries by 51.4% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock valued at $559,622,000 after acquiring an additional 11,334,780 shares in the last quarter. Phoenix Financial Ltd. grew its stake in Teva Pharmaceutical Industries by 31.7% in the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock valued at $632,882,000 after purchasing an additional 9,094,372 shares during the last quarter. Nuveen LLC bought a new position in Teva Pharmaceutical Industries in the first quarter worth about $40,827,000. Assenagon Asset Management S.A. raised its holdings in Teva Pharmaceutical Industries by 41.1% in the second quarter. Assenagon Asset Management S.A. now owns 8,445,992 shares of the company’s stock worth $141,555,000 after purchasing an additional 2,462,064 shares in the last quarter. Finally, Ion Asset Management Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock valued at $599,945,000 after buying an additional 2,383,500 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. UBS Group increased their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Finally, JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $25.86.

Teva Pharmaceutical Industries Trading Down 3.4%

Teva Pharmaceutical Industries stock opened at $24.56 on Tuesday. The stock has a 50-day moving average price of $20.50 and a 200 day moving average price of $18.30. The company has a market capitalization of $28.17 billion, a price-to-earnings ratio of -153.48, a price-to-earnings-growth ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $26.38. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.10. The company had revenue of $4.48 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. Teva Pharmaceutical Industries’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director owned 495,000 shares in the company, valued at $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.